Determinants of Mortality among Cervical Cancer Patients Attending in Tikur Anbessa Specialized Hospital, Ethiopia: Institutional-Based Retrospective Study

Table 2

Clinical and treatment-related characteristics and mortality related to these characteristics among cervical cancer patients in TASH.

Variables	Category	Response	Mortality
			Yes	No
		N (%)	N (%)	N (%)
Stage	Early	457 (43.24)	81 (17.72)	376 (82.28)
	Late	600 (56.76)	228 (38.00)	372 (62.00)
Comorbidity	Yes	344 (32.54)	161 (46.80)	183 (53.20)
	No	713 (67.46)	148 (20.76)	565 (79.24)
Types of comorbidities	HIV	194 (55.91)	99 (51.03)	95 (48.97)
	Hypertension	79 (22.77)	32 (40.51)	47 (59.49)
	Others	74 (21.33)	31 (41.89)	43 (58.11)
Anemia	Yes	541 (51.18)	230 (42.51)	311 (57.49)
	No	516 (48.82)	79 (15.31)	437 (84.69)
Histopathology	Squamous cell	959 (90.73)	279 (41.89)	680 (70.91)
	Adenocarcinoma	98 (9.27)	30 (30.61)	68 (69.39)
Treatment initiated	Sur and chemo	17 (1.60)	4 (23.53)	13 (76.47)
	Chemo	19 (1.80)	3 (15.79)	16 (84.21)
	Radiotherapy	520 (49.2)	147 (28.27)	373 (71.73)
	Chemo and RT	375 (35.4)	125 (33.33)	250 (66.67)
	Sur and RT	111 (10.5)	23 (20.72)	88 (79.28)
	Chemo + Sur + RT	15 (1.4)	7 (46.67)	8 (53.33)
Aim of RT	Radical	388 (36.71)	75 (19.33)	313 (80.67)
	NO RT	46 (4.35)	5 (10.87)	41 (89.13)
	Palliative	623 (58.94)	229 (36.76)	394 (63.24)

Note: Sur = surgical treatment; chemo = chemotherapy; RT = radiation therapy.